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Objective: Aortic root replacement for prosthetic aortic valve endocarditis with
accompanying destruction of the aortic root is a well-established surgical interven-
tion. However, there is still no consensus whether prosthetic material or allogeneic
material should be used. Here we report on our experience with prosthetic composite
and aortic allograft root replacement in such patients during a 10-year interval.
Methods: From 1991 through 2001, 29 patients with prosthetic aortic valve endo-
carditis combined with aortic root destruction underwent reoperation at our insti-
tution. Sixteen patients received aortic root replacement with a cryopreserved aortic
root allograft (group A) and 13 with a prosthetic composite graft (group B). The
interval between the initial operation and reoperation was 29 months (range, 5-168
months) in group A and 55 months (range, 7-248 months) in group B.
Results: Hospital mortality was 18.5% (n  5 patients, 3 in group A and 2 in group
B). Median follow-up was 21 months (range, 1-48 months) for group A and 34
months (range, 1-152 months) for group B (P  .2). Survival at 1 and 5 years was
81% 10% and 81% 10% in group A and 85% 10% and 85% 10% in group
B, respectively. No patient underwent reoperation for recurrent prosthetic aortic
valve endocarditis.
Conclusions: Our results indicate that excellent long-term results can be achieved
regardless of the material used for aortic root replacement in patients with prosthetic
aortic valve endocarditis.
Prosthetic valve endocarditis (PVE) is an important complication afteraortic valve replacement. Blumberg and associates1 described infec-tious destruction of the aortic root in 56% to 100% of these patients.The associated hospital mortality for these patients can reach as highas 30%.2-4 Thorough debridement of infected prosthetic material andinfected tissue, re-replacement of the entire aortic root, and prolonged
antibiotic therapy are all accepted strategies for the treatment of PVE.5-10 However,
there is still debate whether to use biologic material (homograft, autograft, or
xenograft) or prosthetic material in these patients.2,5,6,8-16
In this retrospective study we reviewed the clinical data and outcomes for 29
patients who underwent reoperation for PVE associated with infectious destruction
of the aortic root with homograft or composite aortic root replacement from 1991
through 2001 to elucidate whether the material used for aortic root replacement in
PVE has any influence on short-term and long-term outcome.
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Material and Methods
In a 10-year period between 1991 and 2001, 29 patients underwent
reoperation for PVE with infectious destruction of the aortic root
after aortic valve or composite replacement in our institution (6
women and 23 men; mean age, 51 14 years; range, 23-81 years).
According to the surgeon’s preference, either homograft aortic root
replacement (group A, n  16) or composite aortic root replace-
ment (group B, n  13) was performed. All patients were in New
York Heart Association functional class III and IV preoperatively.
Nine patients had severe preoperative complications, such as car-
diogenic shock. Patient data, including information on the preop-
erative complications, are depicted in Table 1.
Sepsis was defined as a temperature of greater than 38°C,
increased cardiac output, low systemic vascular resistance, and
low oxygen extraction ratio. Acute renal failure was defined as a
rapid decrease of glomerular filtration, with a subsequent progres-
sive increase of serum creatinine, blood urea nitrogen, and elec-
trolyte imbalance and the development of metabolic acidosis ac-
companied by oliguria (500 mL of urine output in 24 hours) or
anuria. Low cardiac output was defined as a mean arterial pressure
of less than 60 mm Hg in the presence of a cardiac index of less
than 2 L · min1 · m2, with a mean right atrial pressure of 18 mm
Hg or greater and a mean left atrial pressure of 18 mm Hg or
greater.
Detected Infectious Microorganisms Causing PVE
PVE was caused mainly by Staphylococcus aureus (n  12
[41%]), and in 6 (21%) patients the infectious microorganism
could not be detected (Table 2).
Surgical Technique
Operations were performed with moderate hypothermia in 24
(83%) patients. However, in 5 (17%) patients deep hypothermia
was chosen for aortic arch surgery. For myocardial protection,
either cold crystalloid cardioplegia or cold blood cardioplegia was
used. The infected prosthetic aortic valves or composite grafts
were completely excised. Abscess cavities were opened, curetted,
washed out with iodine solution, and filled with a gentamicin-
saturated fibrin glue, as described by Karck and coworkers.17
Macroscopically infected or necrotic tissue was widely resected,
regardless of the proximity of the conduction system. Reconstruc-
tion of the aortic annulus with autologous pericardium or glutar-
aldehyde-fixed bovine pericardium was performed in 4 patients
(group A, n 1; group B, n 3). Homograft implantation into the
aortic root was carried out with interrupted monofilament suture
material (4-0 Prolene, Ethicon). Mechanical composite grafts (St
Jude Medical, n  3; Carbomedics n  9; ATS, n  1) were
implanted with single Teflon-armed sutures. Coronary buttons
were reimplanted with a continuous monofilament suture (5-0
Prolene, Ethicon). The distal anastomosis was carried out with a
continuous monofilament suture (4-0 or 3-0 Prolene, Ethicon).
Valve prostheses, Dacron prostheses, and Teflon patches were
incubated in gentamicin solution before implantation for 5 min-
utes.
In addition, the sewing ring of the prosthesis was irrigated with
a mixture of fibrin glue and gentamicin before implantation. In 12
(41%) patients additional surgical procedures were performed, as
depicted in Table 3.
Postoperative Antibiotic Therapy
Patients received antibiotic therapy specifically directed against
the detected microorganisms. If the microorganism could not be
isolated, broad-spectrum antibiotic therapy was administered (van-
comycin and broad-spectrum gram-negative coverage). In all pa-
tients intravenous antibiotic therapy was maintained for 6 weeks
postoperatively.
Statistical Analysis
Data are expressed as medians with ranges or as the mean  SD
where appropriate. Demographic and baseline variables were an-
alyzed by using the Student t test for continuous variables and the
Fisher exact test for qualitative variables. Analysis of survival was
performed by using the Kaplan-Meier method. Statistical differ-
ences in Kaplan-Meier survival estimates were determined by
using the log-rank test. Statistical analyses were performed by
using the SPSS for Windows software package (SPSS Inc).
Results
Five (18.5%) patients died during the hospital stay, 3
(18.7%) in group A and 2 (15.3%) in group B. One patient
TABLE 1. Patient data and preoperative complications
Characteristic
Group A
(n  16)
Group B
(n  13)
P
value
Men (n [%]) 13 (81.2%) 10 (76.9%) .2
Mean age (y)* 61 (37-72) 48 (23-81) .2
Mean follow-up (mo)* 21 (1-48) 34 (1-152) .2
Time between initial
operation and
reoperation (mo)*
29 (5-168) 55 (7-248) .54
Mean preoperative NYHA
functional class
3.7 0.49 3.8 0.45 .2
Cardiogenic shock (n
[%])
2 (12.5%) 2 (15.3%) .2
Septic (n [%]) 7 (43.8%) 6 (46.1%) .2
Septic embolism (n [%]) 2 (12.5%) 1 (7.7%) .2
Acute renal failure (n
[%])
3 (18.8%) 2 (15.3%) .2
Preoperative artificial
ventilation (n [%])
3 (18.8%) 3 (23.1%) .2
NYHA, New York Heart Association.
*Data are expressed expressed as medians with ranges. Note that some
patients had more than one preoperative complication.
TABLE 2. Organism cultured from blood or intraoperative
specimen
Organism
Group A
(n  16)
Group B
(n  13) P value
Enterococcus faecalis (n [%]) 4 (25%) 4 (30.8%) .2
Staphylococcus aureus (n [%]) 6 (37.5%) 6 (46.1%) .2
Candida albicans (n [%]) 2 (12.5%) 1 (7.7%) .2
Not known (n [%]) 4 (25%) 2 (15.3%) .2
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in group A died in the operating room as a result of therapy-
refractory low cardiac output syndrome. Two patients in
each group died of cardiac causes or multiorgan failure
within the first 14 days after the operation. The majority of
patients in both groups experienced a complicated postop-
erative course, and a significant number of postoperative
complications were observed (Table 4). The most common
postoperative complication in both groups was acute renal
failure requiring temporary hemodialysis. The mean stay in
the intensive care unit was prolonged in all patients (group
A: 5  3 days [range, 2-28 days]; group B: 6  4 days
[range, 3-36 days]; P  .2).
Median follow-up was 21 months (range, 1-48 months)
for group A and 34 months (range, 1-152 months) for group
B (P  .2). No patients were lost to follow-up. During
follow-up, no recurrent prosthetic valve endocarditis was
diagnosed, and no patient had to undergo reoperation. Sur-
vival at 1 and 5 years was 81%  10% and 81%  10% in
group A and 85%  10% and 85%  10% in group B,
respectively (P  .2, Figure 1).
Discussion
The results of this study indicate that the material (biologic
vs prosthetic) used for aortic root replacement has no effect
on hospital mortality, long-term mortality, and the incidence
of recurrent PVE in patients requiring redo aortic root
surgery for PVE associated with infectious destruction of
the aortic root.
The surgical goal in the treatment of PVE combined with
infectious destruction of the aortic root is a low rate of
recurrent PVE. It has been argued that the use of homograft
material as a valve substitute in the setting of PVE with
infectious destruction of the aortic root is associated with a
lower mortality and a lower incidence of recurrent PVE
compared with prosthetic material.9-11 We were not able to
detect any differences regarding hospital mortality between
the groups (group A, 18.7%; group B, 15.4%; P  .2). The
overall mortality in our study cohort of 18.7% is comparable
with what other investigators have previously reported. In
the most recent studies, hospital mortality for PVE varied
between 9.4% and 32%.2-4,8-10 Moreover, a meta-analysis
from the United Kingdom heart valve registry showed a
similar mortality rate averaging 20%.18 The second impor-
tant issue in the treatment of PVE beside mortality is the
incidence of recurrent PVE. Delay and coworkers19 dem-
onstrated that surgical intervention for PVE can be per-
formed with no hospital deaths; however, in this study
freedom from reoperation was only 45% after 1 year.
We speculate that this might be the result of an intraop-
erative eradication failure of the underlying organism from
the aortic root. In our patient population we had no recurrent
PVE with a total follow-up of 47 44 months (range, 1-152
months). Lytle and associates9 showed a recurrent rate of
3.8% within 1 year after surgical intervention for PVE by
using homograft aortic root replacement as the second pro-
cedure. Hagl and colleagues10 demonstrated, with an almost
identical patient cohort, a 4% recurrence rate for PVE after
using prosthetic composite graft replacement for the treat-
ment of PVE. In both series the entire aortic root was
replaced either with homografts or prosthetic material.
These findings might support the strategy of using aggres-
sive surgical intervention to replace the aortic root in pa-
tients presenting with PVE. Data comparing the effect of
biologic (homograft-autograft) material or prosthetic mate-
rial on outcome in patients with PVE and infectious aortic
root replacement are rare. Haydock and coworkers,11 as
well as and McGiffin and associates,12 underlined the ad-
vantage of homograft aortic root replacement for PVE as-
sociated with annular destruction in a comparative study
comparing homograft versus prosthetic aortic replacement
for PVE. However, none of these studies were randomized,
and the number of patients involved was limited. Recent
published studies dealing with the problem of PVE and
infectious destruction of the aortic root showed excellent
TABLE 3. Intraoperative data
Group A
(n  16)
Group B
(n  13) P value
CPB time (min)* 203 (149-363) 172 (85-268) .047
Crossclamp time (min)* 132 (97-177) 107 (54-127) .034
Circulatory arrest (n
[%])
3 (18.7%) 2 (15.4%) .2
Concomitant procedure
MVS (n [%]) 2 (12.5%) 1 (7.7%) .2
Aortic arch
replacement (n [%])
2 (12.5%) 2 (15.4%) .2
CABG (n [%]) 3 (18.7%) 1 (7.7%) .04
CPB, Cardiopulmonary bypass; MVS, mitral valve surgery; CABG, coronary
artery bypass grafting.
*Data are expressed expressed as medians with ranges.
TABLE 4. Perioperative complications
Complication
Group A
(n  16)
Group B
(n  13) P value
Hospital mortality (n [%]) 3 (18.7%) 2 (15.3%) .2
Atrioventricular block III°
(n [%])
4 (25%) 2 (15.4%) .013
Stroke (n [%]) 2 (12.4%) 1 (7.7%) .2
Acute renal failure (n [%]) 7 (43.7%) 8 (61.5%) .2
Low cardiac output
syndrome (n [%])
3 (18.7%) 4 (30.8%) .2
Prolonged artificial
ventilation, 48 h (n
[%])
6 (37.5%) 8 (61.5%) .2
Note that some patients had more than one postoperative complication.
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short-term and long-term results: one group used homograft
material, and the other group used prosthetic material for
aortic root replacement in the presence of PVE.9,10 The
results from these studies did not differ in terms of short-
and long-term survival or in the incidence of recurrent PVE.
From these studies and our own results, we believe that
other factors in addition to the material used for the treat-
ment of PVE might influence the outcome. Delahaye and
associates20 showed that undue delay of operation for en-
docarditis is common and that the delay in surgical treat-
ment might result in more severe infectious destruction of
cardiac structures, with all resulting consequences. Further-
more, a more aggressive surgical approach to the treatment
of PVE seems to influence the outcome.10,21 Hagl and
associates10 stressed that patients presenting with PVE com-
bined with infection beyond the valve annulus are best
treated with aortic root replacement rather than aortic valve
replacement and repair of annular destruction because of
decreased hospital mortality after aortic root replacement.
In our opinion a radical surgical approach with resection of
all infectious and necrotic tissue regardless of the cardiac
structures involved followed by complete aortic root re-
placement might be the clue to success in the treatment for
PVE with infectious destruction of the aortic root.
Limitations
We wish to address several limitations. First, the number of
patients in each group is too small to draw definite conclu-
sions concerning the material that should be used in PVE
with infectious destruction of the aortic root. However, in
the most recent publications, the patient cohort with com-
plicated PVE was almost similar to ours.6,9,10 Second, pa-
tients were not prospectively randomized, and the selection
for either homograft or prosthetic aortic root replacement
was dependent on the surgeon’s preference only. Further-
more, the severity of the infection and the causative micro-
organism might vary between different patient cohorts.
Conclusions
Keeping all the aforementioned drawbacks of this study in
mind, we believe that the material used for aortic root
replacement in PVE with infectious destruction of the aortic
root has no major effect on postoperative outcome. The
strategy of early reoperation for PVE, thorough debride-
ment, aggressive surgical technique, and prolonged antibi-
otic treatment might reduce mortality and the incidence of
early and late recurrent PVE and improve long-term sur-
vival.
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